Quantbot Technologies LP Sells 421 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Quantbot Technologies LP lowered its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 12.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,863 shares of the biopharmaceutical company’s stock after selling 421 shares during the quarter. Quantbot Technologies LP’s holdings in Agios Pharmaceuticals were worth $94,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AGIO. State Street Corp grew its stake in shares of Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after purchasing an additional 216,484 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Agios Pharmaceuticals by 15.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company’s stock valued at $531,000 after buying an additional 1,570 shares during the last quarter. FMR LLC increased its stake in shares of Agios Pharmaceuticals by 283.2% in the 3rd quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock valued at $2,017,000 after buying an additional 33,546 shares during the period. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $33,000. Finally, Franklin Resources Inc. acquired a new position in shares of Agios Pharmaceuticals during the third quarter valued at $1,499,000.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.93% of the stock is owned by insiders.

Agios Pharmaceuticals Trading Down 3.2 %

AGIO stock opened at $29.30 on Tuesday. Agios Pharmaceuticals, Inc. has a 1-year low of $27.14 and a 1-year high of $62.58. The firm has a market cap of $1.68 billion, a PE ratio of 2.58 and a beta of 0.90. The business’s 50-day moving average price is $33.11 and its two-hundred day moving average price is $40.71.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Scotiabank increased their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Royal Bank of Canada raised their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and a consensus target price of $56.57.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.